Bioequivalence of mirabegron 50 mg extended release Tablet [Design Issues]

posted by Ibrahim Komeil – Egypt, 2021-02-20 12:36 (711 d 08:10 ago) – Posting: # 22218
Views: 2,839

Dear All
I had performed a 2X2 crossover study between test and reference product of mirabegron 50 mg under fasting conditions where 34 volunteers were completed the study.

Knowing that I couldn't find an accurate data for intrasubject variability of Mirabegnon. The results showed a very high unexpected intra-subject variability as following:
Cmax: 73.8451%, AUCt: 67.6524%
I calculated study power too and it results as following:
Cmax: 38.45% and AUCt: 42.38%

Therefore, a sequential two stage study won't be applicable in that condition. My question is: If i repeat the aforementioned study again, shall i follow a partial replicated cross over design or full replicated cross over design?

My second: Shall i follow RASBE or unscaled BE limits ?

Thanks in advance

Complete thread:

UA Flag
 Admin contact
22,478 posts in 4,708 threads, 1,603 registered users;
10 visitors (0 registered, 10 guests [including 6 identified bots]).
Forum time: 20:47 CET (Europe/Vienna)

I think it is much more interesting to live with uncertainty
than to live with answers that might be wrong.    Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz